Gold’s relentless rally has nudged the precious metal to the brink of $4,000 per ounce, carving out its biggest annual advance since 1979 amid political upheaval and a sharply deteriorating macroeconomic outlook. With the US government mired in a prolonged shutdown and France roiled by new fiscal concerns, investors have flocked to gold, driving spot prices as high as $3,976 in recent trading sessions and putting the symbolic $4,000 target within reach. Currently, the SPDR Gold Shares ETF (GLD) closed at $364.38 and is up +48.73% over the last year.
Uncertainty, Central Banks, and Safe-Haven Demand
Much of gold’s rally this year has hinged on the disruptive cocktail of central bank buying, shifting monetary policy expectations, and growing doubts over the stability of sovereign assets traditionally seen as safe. The Federal Reserve’s monetary policy remains clouded by the shutdown, depriving investors—and policymakers themselves—of crucial data to gauge economic health, while consensus builds that rate cuts may occur before year’s end. These conditions have sent gold’s appeal soaring: As a non-yielding asset, gold thrives when real interest rates fall, and global buyers have responded by pouring record sums into gold-backed ETFs and physical bullion.
Central banks have emerged as powerful influencers in this rally, rebounding from a brief pause in July to add another 15 tonnes to reserves in August alone, according to the World Gold Council. Poland remains the year’s largest sovereign buyer, while demand has picked up from Kazakhstan, Bulgaria, and El Salvador, underscoring a structural shift in global reserve management away from the US dollar. Central banks now hold around 36,000 tonnes of gold, the highest proportion of reserves in three decades.
Analyst Projections and What Comes Next
Major banks have updated their forecasts in rapid succession as gold eyes further milestones. HSBC, Bank of America, and Goldman Sachs (GS) are collectively targeting prices in a trading range from $3,800 to $4,100 through yearend and into 2026, with forecasts stretching as high as $4,900 per ounce by December 2026 if current demand trends persist. J.P. Morgan (JPM) projects gold averaging $3,675 in Q4 2025 and approaching $4,000 in the first half of 2026, as central banks continue diversifying out of dollar reserves and ETF inflows remain strong.
Worries over inflation, the deteriorating US fiscal outlook, and persistent geopolitical instability have replaced long-standing faith in Treasuries as the ultimate safe haven, prompting central banks and institutional investors to reassess gold’s role in portfolio hedging. The bullish stance is reflected in survey and AI-driven forecasts: BullionVault users, for example, now project an average Q4 2025 price as high as $3,679, well above analyst forecasts from the LBMA and other institutional sources.
The Search for Safety—And Its Limits
The feverish demand has not been without consequence. Rapid price gains have prompted some tactical selling by smaller central banks and private holders, and the rally itself could eventually cool if political tensions or rate-cut bets abate. Yet for now, gold’s surge remains anchored in deep investor anxieties and structural changes in the reserve landscape, making new highs likely as uncertainty lingers.
The Sum…
If recent history is any guide, the precious metal may not stop at $4,000—a milestone that reflects more than just fear, but also a global recalibration of what it means to be “safe.”
The Sources
- https://www.share-talk.com/gold-is-closing-in-on-the-4000-per-ounce-mark-hitting-fresh-record-highs/
- https://finance.yahoo.com/news/gold-heads-closer-4-000-224248779.html
- https://finance.yahoo.com/news/gold-hits-another-record-high-234410111.html
- https://www.gold.org/goldhub/gold-focus/2025/10/central-bank-gold-statistics-central-bank-gold-buying-rebounds-august
- https://www.forbes.com/sites/roystonwild/2025/10/03/central-banks-add-15-tonnes-of-gold-in-august-says-world-gold-council/
- https://finance.yahoo.com/news/gold-fomo-could-push-metal-130058078.html
- https://www.jpmorgan.com/insights/global-research/commodities/gold-prices
- https://www.reuters.com/markets/commodities/golds-rise-central-bank-reserves-appears-unstoppable-2025-09-04/
- https://sg.news.yahoo.com/gold-hits-record-high-above-140204505.html
- https://www.kitco.com/news/article/2025-10-03/central-banks-were-big-buyers-gold-again-august-world-gold-council
- https://discoveryalert.com.au/news/gold-rally-2025-record-surge-outlook-drivers/
- https://www.reuters.com/business/goldman-hikes-december-2026-gold-price-forecast-4900oz-2025-10-07/
- https://www.goldmansachs.com/insights/articles/gold-forecast-to-rise-by-the-middle-of-2026
- https://investinghaven.com/forecasts/gold-price-prediction/
- https://www.bullionvault.com/gold-news/infographics/ai-gold-precious-metal-price-forecasts
- https://www.marketpulse.com/markets/gold-xauusd-set-to-challenge-4000-as-prices-renew-all-time-highs-in-todays-session-potential-targets-and-price-forecast/
- https://www.businessinsider.com/gold-price-outlook-prediction-bullion-10k-2030-central-bank-demand-2025-10
- https://economictimes.com/news/international/us/gold-price-prediction-gold-rates-in-october-predicted-by-bullion-experts/articleshow/124291879.cms
- https://coincodex.com/precious-metal/gold/forecast/
- https://www.gold.org/goldhub/research/central-bank-gold-reserves-survey-2025
Advanced Micro Devices (NasdaqGS: AMD) soared on Monday after signing a blockbuster, multiyear supply agreement with OpenAI that could redefine the balance of power in the red-hot artificial intelligence chip market. Under the terms, OpenAI will purchase up to 6 gigawatts of AMD’s latest-generation Instinct GPUs — a commitment believed to put tens of billions in revenue on AMD’s ledger and grant OpenAI the right to acquire as much as 10% of AMD’s equity if both parties meet ambitious milestones.
AMD Secures Transformative AI Partnership
The deal, detailed by executives from both companies, marks AMD’s largest-ever single customer contract and a major strategic pivot for OpenAI as it seeks to broaden its hardware supply chain beyond Nvidia — the current industry heavyweight. Beginning with a 1-gigawatt rollout in 2026 using AMD’s forthcoming MI450 series chips, the multi-phase plan will see OpenAI deploy up to 6 gigawatts of compute capacity across several chip generations, with further tranches dependent on performance and financial milestones.
Financial Structure Ties AI Ambitions to AMD Stock
A distinctive element of the announcement is the innovative equity structure: OpenAI has been issued warrants to buy up to 160 million AMD shares at one cent each—amounting to nearly 10% of the company—if it rolls out chips at scale and if AMD’s share price meets successive targets, culminating in a $600-per-share threshold for the final tranches. This arrangement, which market analysts interpret as “structural reconfiguration” of AI infrastructure financing, sharply aligns the future success of both firms, effectively tying AMD’s long-term valuation to the acceleration of OpenAI’s infrastructure projects.
Market Reaction and Wider Implications
Following the news, AMD shares soared as much as 30% in Monday trading—marking the chipmaker’s largest single-day surge since 2016 and lifting the tech-heavy Nasdaq index in the process. Analyst commentary widely framed the agreement as a direct challenge to Nvidia’s dominance, with AMD’s leadership touting the partnership as transformative not just for the company, but for the broader semiconductor ecosystem.
The Sum…
OpenAI, for its part, is expected to maintain some Nvidia (NVDA) purchases going forward, but the AMD deal signals a broader industry pivot as major AI developers pursue greater resilience and optionality in their supply chains. The strategic wager is clear: as AI demand outstrips supply, chip customers and vendors alike are reimagining alliances, shifting the sector’s tectonic plates in the process.
The Sources
- https://www.reuters.com/business/amd-signs-ai-chip-supply-deal-with-openai-gives-it-option-take-10-stake-2025-10-06/
- https://www.forbes.com/sites/siladityaray/2025/10/06/amd-shares-surge-30-after-multibillion-dollar-deal-with-openai/
- https://www.morningstar.com/news/marketwatch/20251006105/amds-stock-soars-toward-its-best-day-in-9-years-heres-why-openai-wants-a-stake
- https://www.cnbc.com/2025/10/06/openai-amd-chip-deal-ai.html
- https://finance.yahoo.com/news/amd-stock-rockets-higher-on-multibillion-dollar-openai-deal-125503782.html
- https://www.wsj.com/tech/ai/openai-amd-announce-massive-computing-deal-marking-new-phase-of-ai-boom-ed92cc42
- https://apnews.com/article/openai-chatgpt-ai-chips-a4714748ede46621863f4860f608ac98
- https://fortune.com/2025/10/06/amd-stock-jumps-on-openai-deal-as-big-tech-seeks-to-reduce-reliance-on-nvidia/
- https://finance.yahoo.com/news/amd-supply-6gw-compute-capacity-133326736.html
- https://www.investopedia.com/openai-and-amd-announce-massive-ai-partnership-sending-amd-shares-soaring-11824659
- https://morethanmoore.substack.com/p/amd-and-openai-the-6-gigawatt-bet
- https://www.cnbc.com/2025/10/05/stock-market-today-live-updates.html
- https://www.reuters.com/business/wall-street-futures-rise-investors-focus-ai-rate-cut-themes-2025-10-06/
- https://www.cnbc.com/2025/10/06/openai-hands-amd-a-big-win-in-ai-chip-race-what-does-it-mean-for-nvidia.html
- https://www.wsj.com/tech/ai/openai-amd-deal-ai-chips-ed92cc42
- https://ir.amd.com/news-events/press-releases/detail/1260/amd-and-openai-announce-strategic-partnership-to-deploy-6-gigawatts-of-amd-gpus
- https://www.bloomberg.com/news/articles/2025-10-06/openai-signs-amd-chips-deal-worth-tens-of-billions-of-dollars
- https://abc7.com/post/us-stocks-tick-records-amd-deal-openai-support-artificial-intelligence-infrastructure-leads/17951277/
- https://ca.finance.yahoo.com/news/stock-market-today-dow-falls-while-sp-500-nasdaq-rise-as-amd-surges-on-openai-deal-133132738.html
- https://www.youtube.com/watch?v=WuXCNpbO9hI
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is scripting an uncommon chapter in biotech, bringing together seasoned leadership, investor-grade science, and strategic capital to tackle the field’s toughest clinical problems—all at a moment when the market is demanding both durability and dynamism from its innovators. The company’s recent video, “Advancing Biotech Through Leadership and Innovation,” captures this ethos, with CEO Steve Ledger at the helm and a board comprised of industry luminaries, including serial biotech builder Simba Gill.
Leadership Drives Momentum
At the heart of Serina’s strategy is Ledger’s philosophy: talent and teamwork attract capital, and capital enables innovation. The narrative is reinforced by recent hires—accomplished names like Greg Curhan (CFO) and board members Jay Venkatesan, MD, MBA and Steve Brannan, M.D., each with multi-billion dollar exits, joined by drug development expert Richard Marshall, recognized with honors from the Queen of England. This aggregation of industry veterans signals more than ambition; it signals a relentless pursuit of scientific and operational excellence, especially as generalist investors remain in retreat and sector valuations hover at historic lows.
Platform Technology Redefines Drug Development
Serina’s POZ Platform™—a proprietary polymer drug optimization technology—has drawn interest not just for its chemical innovation but for its clinical practicality. Ledger describes the platform as “remarkable,” offering precise control in drug release and an ability to upgrade existing therapeutics with enhanced efficacy and safety. The lead asset, SER-252, exemplifies the approach: it leverages continuous dopaminergic stimulation to target motor fluctuations in advanced Parkinson’s patients. Backed by FDA support for its streamlined 505(b)(2) NDA pathway, the company is set to initiate its first patient dosing in Australia in Q4 2025, followed by U.S. enrollment in Q1 2026.
Financial Path and Strategic Vision
Serina has secured up to $20 million in flexible, milestone-based financing led by Dr. Greg Bailey—known for his early role at Biohaven (BHVN) and Juvenescence—tailored to align funding with clinical trial achievements. This strategic structure mitigates risk and extends runway through a capital-efficient lens, echoing Ledger’s view that “only firms with robust backing and diversified portfolios have continued to attract investment” in today’s lean environment. With additional candidates in the pipeline (including SER-270 for tardive dyskinesia) and explorations into Huntington’s disease, Serina is stacking clinical “shots on goal,” positioning itself as a competitor able to pivot and scale across neurological indications.
Innovation Culture and Industry Context
If the industry’s next trillion-dollar company is to be found in biotech, as Simba Gill suggests, Serina aims to be a contender—betting on better science and smarter teams, not just silver bullet molecules. The firm’s narrative is spliced with lessons from the wider sector: capital scarcity breeds discipline, while “entrepreneurs must believe they can do something the rest of the world either failed or never considered”. For Serina, investing in enabling platforms and exceptional leadership is an offensive move—a bid to not simply survive the downturn but to define the next wave of biotech value creation.
The Sum…
In the end, Serina Therapeutics (NYSE American: SER) illustrates how world-class leadership and technological ingenuity can infuse both hope and rigor into the world of drug development—demonstrating that even in lean seasons, the right combination of talent, timing, and vision can make all the difference.
The Sources
- https://www.youtube.com/watch?v=5T1DRa7xTRA
- https://vistap.aryuenterprises.com/serina-therapeutics-ceo-why-now-is-the-time-to-invest-in-biotech-ser-ibb-xbi/
- https://podcast.jesslarsen.net/simba-and-steve/
- https://trial.medpath.com/news/612b4282b7943263/serina-therapeutics-advances-parkinson-s-treatment-with-ser-252-clinical-trials-set-for-2025
- https://www.stocktitan.net/news/SER/serina-therapeutics-announces-fda-feedback-supports-registrational-8glwmyn2n9i4.html
- https://vistap.aryuenterprises.com/biotech-breakthrough-serina-therapeutics-secures-insider-led-financing-for-ser-252-registrational-trial-in-neurology-pipeline-ser-bhvn-xbi/
- https://www.globenewswire.com/news-release/2025/09/09/3147306/0/en/Serina-Therapeutics-Secures-Up-to-20-Million-to-Advance-Registrational-Trial-of-SER-252-in-Parkinson-s-Disease.html
- https://www.linkedin.com/posts/serina-therapeutics-inc._linkedin-video-activity-7378504246075379712-mgUU
- https://www.linkedin.com/posts/serina-therapeutics-inc._linkedin-video-activity-7375974996114022402-U2FF
- https://www.linkedin.com/company/serina-therapeutics-inc.
- https://www.biospace.com/press-releases/serina-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-highlights
- https://finance.yahoo.com/news/serina-therapeutics-present-btig-virtual-100000037.html
- https://www.serinatx.com
- https://www.stocktitan.net/news/SER/serina-therapeutics-to-present-at-force-family-office-investor-6olwknlab217.html
- https://www.linkedin.com/posts/serina-therapeutics-inc._linkedin-video-activity-7360762412762877952-0SCF
- https://www.barchart.com/story/news/30077271/serina-therapeutics-ceo-steven-a-ledger-to-discuss-continuous-drug-delivery-for-parkinsons-disease-at-upcoming-webinar
- https://www.youtube.com/watch?v=UoAO8bJ9TwE
- https://finance.yahoo.com/quote/SER/press-releases/
- https://www.youtube.com/watch?v=OdZpjhnnsiY
- https://www.stocktitan.net/news/SER/serina-therapeutics-secures-up-to-20-million-to-advance-uericgwjesp2.html
Amarin Corporation (NASDAQ: AMRN), a company that envisions a world where cardiovascular disease is NOT the leading cause of death worldwide, seemingly presents itself as a deep-value opportunity, trading near its cash value yet is believed to be poised for a turnaround driven by strategic shifts and international expansion. The company’s stock valuation currently reflects its liquidation value, but several catalysts suggest substantial upside potential as it retools its global strategy amid challenges in its core U.S. market.
Activist Joined Board
Amarin’s transformation has been propelled notably by the April 2025 appointment of activist investor Michael Torok to the board. Torok’s involvement has accelerated a rigorous strategic review aimed at enhancing shareholder value, operational efficiency, and capital allocation discipline. This governance change marks a pivotal driver for reshaping Amarin’s future prospects. The company has also advanced a leaner, more targeted commercial strategy in the U.S., where Vascepa—its flagship cardiovascular drug—has grappled with significant generic competition following patent expirations. Instead of broad sales efforts, Amarin now focuses on cardiologists who prioritize Vascepa’s differentiated clinical data, sustaining a profitable branded niche and stabilizing revenue amidst a challenging U.S. environment.
Vascepa Growth
International markets are becoming the cornerstone of Amarin’s growth narrative. A landmark licensing agreement with Italy’s Recordati last June granted European commercialization rights for Vascepa (branded Vazkepa in Europe), including $25 million upfront and potential milestone payments totaling $150 million, plus royalties. This deal significantly lightens Amarin’s commercial burden while unlocking access to an estimated 45 million statin patients in Europe. Enhanced penetration potential and revenue generation from this market are key components of Amarin’s pivot to profitability.
China represents another critical growth catalyst, with national regulatory approval for Vascepa secured in mid-2024 via partner EddingPharm. This paves the way for reimbursement inclusion anticipated to begin generating material revenue in 2026. With approximately 36 million statin patients in China, even a conservative 2% market penetration translates into substantial royalty income for Amarin, alongside a $15 million milestone payment already earned. China’s vast patient base and expanding cardiovascular market could accelerate Amarin’s revenue trajectory meaningfully.
The Financials
Financially, Amarin reported an 8% year-over-year revenue increase to $72.7 million in Q2 2025, boosted by offshoot revenue streams including European royalties. Yet, net losses persist as the company invests in restructuring and expanding global presence. Despite this, the balance sheet remains healthy with nearly $300 million in cash and no debt, providing a cushion that limits downside risk. Analysts forecasts annual free cash flow in the range of $200 to $300 million within five years, supporting a fundamental revaluation from a cash-based to an earnings-driven stock.
Amarin’s strategic evolution and financial profile also render it an attractive acquisition candidate. Large pharmaceutical firms may find value in Amarin’s robust cash position, improving cash flows, expanded international footprint, and especially its tax loss carryforwards exceeding $1.8 billion, which could serve as valuable tax shields post-acquisition.
The Sum…
In summary, Amarin Corporation (NASDAQ: AMRN) is navigating a critical inflection point. The combined effect of activist board-level intervention, disciplined U.S. market management, lucrative European partnerships, and forthcoming Chinese reimbursement approval positions the company for a potential re-rating. Investors are weighing a company trading at near liquidation value but with significant operational and strategic levers primed to unlock global cardiovascular market opportunities and shareholder value. Shares of Amarin are now up +92.94% YTD at $18.84 representing a $389.66M market cap as of the close on Friday.
The Sources
- https://seekingalpha.com/article/4826739-amarin-vascepas-global-pivot-from-u-s-squeeze-to-international-boom
- https://www.amarincorp.com/investor-relations/events-and-presentations/amarin-corporations-second-quarter-2025-results
- https://www.nasdaq.com/articles/validea-kenneth-fisher-strategy-daily-upgrade-report-9-4-2025
- https://crofting.scotland.gov.uk/market-outlook/Why-Amarin-Corporation-plc-Depositary-Receipt-stock-is-a-value-investor-pick
- https://www.investing.com/news/transcripts/earnings-call-transcript-amarin-q2-2025-sees-revenue-beat-stock-stable-93CH-4203411
- https://www.fiercepharma.com/pharma/investor-group-calls-strategy-shift-amarin-shares-continue-flounder-post-sarissa-capital
- https://www.worldpharmaceuticals.net/news/amarin-signs-licensing-deal-with-recordati-for-vazkepa-in-europe/
- https://www.pharmabiz.com/NewsDetails.aspx?aid=170195&sid=2
- https://www.biospace.com/amarin-pharmaceuticals-inc-acquires-parkinson-s-disease-drug-candidate
- https://www.tradingview.com/news/tradingview:23d19edbd95a5:0-amarin-corporation-q2-2025-financial-results/
- https://www.amarincorp.com/news-and-media/amarin-reports-first-quarter-2025-financial-results
- https://www.investing.com/news/company-news/amarin-adds-investment-expert-michael-torok-to-board-93CH-3970449
- https://www.fiercepharma.com/pharma/recordati-pays-25m-front-commercialize-amarins-heart-pill-vascepa
- https://www.amarincorp.com/news-and-media/amarin-partner-eddingpharm-receives-regulatory-approval-0
- https://www.amarincorp.com/news-and-media/amarin-implements-organizational-restructuring-strengthen
- https://finance.yahoo.com/news/expect-amarin-corp-plc-amrn-140026472.html
- https://www.cautionwearcondoms.com/LatestNews/what-catalysts-could-drive-amarin-corporation-plc-depositary-receipt-stock-higher-in-2025
- https://finance.yahoo.com/news/amarin-appoints-jec-capital-partners-113000210.html
- https://www.globenewswire.com/news-release/2025/06/24/3104106/18362/en/Amarin-Announces-Exclusive-License-and-Supply-Agreement-with-Recordati-to-Commercialize-VAZKEPA-Icosapent-Ethyl-in-Europe.html
- https://www.investing.com/news/company-news/china-approves-vascepa-to-reduce-cardiovascular-risk-93CH-3509874
Teladoc Health (TDOC) shares are is surging today. On Aug, 14 Teledoc, the global leader in virtual care, announced an acquisition of Telecare, an Australian pioneer in virtual specialist and allied health services—a move celebrated by Wall Street as turbocharging Teladoc’s international momentum and unlocking new growth avenues. Shares climbed on optimism that the deal positions Teladoc as the go-to platform for specialist virtual care across the Asia-Pacific, underscored by strong trading volume and robust short-term technical signals.
Expanding International Reach
The Telecare acquisition cements Teladoc’s foothold in a region experiencing rapid adoption of digital health, adding over 300 virtual specialists across 30+ specialties to its global network. These services cater to both public hospitals and GP referrals, helping reduce wait times and improve access, especially for rural and underserved Australians. Teladoc’s international business, already accounting for over 15% of consolidated revenue, saw global revenues leap 10% last quarter—a trend analysts believe the Telecare deal will accelerate.
Bullish Stock Performance and Analyst Views
Today’s trading seems to be reflecting renewed investor confidence; Teladoc shares outperformed broader indices with analysts flagging a potential upside of nearly 21% over the next three months, supported by positive long-term technical trends. The buy signals from the longer-term moving averages and the newfound regional market dominance painted a bullish outlook, even as Teladoc continues to expand through acquisitions like Catapult and UpLift earlier this year—anchoring a multi-pronged growth strategy in preventive and mental health.
Strategic Fit and Synergy
Teladoc’s leadership highlighted how the merger fortifies its mission “to support one of the world’s leading health markets,” offering continuity for Telecare’s established management and brand. The deal will enable new virtual solutions, from neonatology to telesurgery, for a healthcare ecosystem hungry for innovative, scalable systems.
The Sum…
Wall Street’s upbeat response seems to signifiy not just confidence in Teladoc’s Australia push, but a broader expectation that international digital health expansion will be a key driver of value and competitive advantage in 2025 and beyond.
The Sources…
- https://www.healthcaredive.com/news/teladoc-acquires-telecare-australia-virtual-care-international-expansion/757808/
- https://stockinvest.us/stock/TDOC
- https://finance.yahoo.com/quote/TDOC/history/
- https://finance.yahoo.com/news/teladoc-health-acquires-telecare-expanding-210000705.html
- https://www.digitalhealthnews.com/teladoc-acquires-telecare-to-expand-international-virtual-healthcare
- https://community.hlth.com/insights/news/teladoc-health-acquires-telecare-to-strengthen-australian-presence-2025-08-18
- https://www.hospitalmanagement.net/news/teladoc-health-australia-telecare-acquisition/
- https://www.gurufocus.com/news/3064684/teladoc-health-tdoc-expands-australian-market-with-telecare-acquisition
- https://finance.yahoo.com/quote/TDOC/
- https://www.teladochealth.com/newsroom/press/teladoc-health-acquires-telecare-expanding-access-to-specialist-and-allied-health-care-for-australians-in-public-and-private-health
- https://www.mobihealthnews.com/news/teladoc-health-acquires-australian-company-telecare
- https://www.healthcareittoday.com/2025/09/12/teladoc-health-acquires-telecare-expanding-access-to-specialist-and-allied-health-care-for-australians-in-public-and-private-health/
- https://www.tipranks.com/news/ratings/teladocs-mixed-performance-and-growth-challenges-lead-to-hold-rating-ratings
- https://www.linkedin.com/posts/lloydgprice_teladoc-health-acquires-telecare-expanding-activity-7362085237415157760-Md63
- https://hitconsultant.net/2025/08/18/teladoc-health-acquires-telecare/
- https://www.investing.com/equities/teladoc-inc-historical-data
- https://seekingalpha.com/article/4818923-teladoc-health-the-upside-is-tantalizing-but-the-risks-are-too-high
- https://www.linkedin.com/posts/allhealthtech_healthtech-virtualcare-mergersandacquisitions-activity-7365776003312312323-gXbn
- https://ir.teladochealth.com/stock-info/stock-quote/default.aspx
- https://finance.yahoo.com/news/teladoc-health-expands-australia-telecare-144754854.html